Status:
NOT_YET_RECRUITING
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions:
Urothelial Carcinoma
Breast Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This prospective phase Il study is aim to evaluate the efficacy and safety of FGFR inhibitor combined with immune checkpoint inhibitors in FGFR1/2/3 variant advanced solid tumors.
Eligibility Criteria
Inclusion
- Age ≥ 18 years;
- Histologically or cytologically confirmed unresectable advanced solid tumors with failure or intolerance to standard treatments;
- At least one measurable lesion per RECIST v1.1 criteria;
- Gene testing confirms FGFR1/2/3 variants, including but not limited to mutations, fusions/rearrangements in solid tumors;
- Patients have not previously used specific small molecule multi-target inhibitors of the FGFR pathway, as assessed by investigators, and have been treated with immune checkpoint inhibitors;
- ECOG performance status of 0-1;
- Expected survival time \> 3 months;
- Laboratory criteria:
- Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L in the past 14 days without granulocyte colony-stimulating factor;
- Platelets ≥ 100 x 10⁹/L without transfusion in the past 14 days;
- Hemoglobin \> 9 g/dL in the last 14 days without transfusion or erythropoietin;
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN), or total bilirubin \> ULN but direct bilirubin ≤ ULN;
- AST, ALT ≤ 2.5 x ULN (≤ 5 x ULN in patients with liver metastasis);
- Serum creatinine ≤ 1.5 x ULN and creatinine clearance (Cockcroft-Gault) ≥ 50 ml/min;
- Good coagulation function, defined as INR or PT ≤ 1.5 x ULN. If on anticoagulant therapy, PT should be within the therapeutic range of anticoagulants;
- Female subjects of reproductive age must have a negative urine or serum pregnancy test within 3 days prior to the first dose (Cycle 1, Day 1). If the urine test is inconclusive, a blood test is required. Non-reproductive females are defined as post-menopausal for at least one year or surgically sterile;
- Subjects with reproductive potential must use contraception with an annual failure rate of less than 1% during treatment and for 120 days after the last study drug dose (or 180 days after the last chemotherapy dose).
Exclusion
- Diagnosis of other malignancies within 3 years before the first dose, except for certain treated skin carcinomas and in-situ carcinomas;
- Previous treatment with selective FGFR inhibitors;
- Receipt of other investigational drugs within 21 days or antitumor drugs within 14 days before the first dose;
- Unresolved toxicity from prior treatments unless ≤ Grade 1 or related to alopecia or fatigue;
- Known symptomatic CNS metastasis or carcinomatous meningitis. Stable patients post-treatment with no evidence of progression may be eligible if steroid-free for at least 14 days;
- History of allogeneic organ or hematopoietic stem cell transplantation;
- Abnormal laboratory parameters:
- Serum phosphate \> 1.5 x ULN;
- Elevated serum calcium or albumin-adjusted calcium outside the reference range;
- Known HIV infection or positive HIV test;
- Active or poorly controlled serious infection;
- Need for drainage treatment for pleural effusion, ascites, or pericardial effusion;
- Active hepatitis B or C infection with high viral load, or positive HBsAg or anti-HCV antibodies. Patients on antiviral therapy must meet lower thresholds;
- Significant uncontrolled heart disease, including recent MI, severe heart failure, or uncontrolled arrhythmias;
- Clinically significant ECG changes or history of significant cardiac issues; Screening QTcF interval \> 480 ms, or JTc interval if applicable, must be ≤ 340 ms;
- Uncontrolled hypertension despite treatment;
- Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh grade B or higher cirrhosis;
- Major surgery within 4 weeks before the first dose or planned major surgery during the study;
- Unresolved complications from prior surgery;
- Pregnant or breastfeeding women, or those planning to become pregnant during the study period and for safety follow-up;
- Radiotherapy within 4 weeks before the first dose, except for non-CNS palliative radiotherapy with a 2-week washout period;
- History of systemic electrolyte imbalance or ectopic soft tissue calcification;
- Clinically significant corneal or retinal disease;
- Use of potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives before the first dose;
Key Trial Info
Start Date :
August 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06551896
Start Date
August 15 2024
End Date
December 31 2026
Last Update
August 13 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.